Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 9/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253935 | 0.88 | HRH3 (0.48) | MAPTHRH3P2RX3P2RX2ALDH1A1 | |
| SCHEMBL4250576 | 0.83 | PDE4B (0.45) | MAPTHRH3P2RX3P2RX2ALDH1A1 | |
| SCHEMBL4255464 | 0.81 | MAPT (0.54) | MAPTRXRALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL6840273 | 0.78 | HRH3 (0.58) | MAPTHRH3RXRAALDH1A1LMNA | |
| SCHEMBL4252380 | 0.78 | MEN1 (0.59) | MAPTL3MBTL1HCAR3LDHA | |
| SCHEMBL4063316 | 0.77 | MEN1 (0.60) | P2RX3P2RX2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1271501 | 0.76 | MAPT (0.57) | MAPTHRH3L3MBTL1CTSALDHA | |
| SCHEMBL8827625 | 0.75 | CXCL8 (0.51) | MAPTL3MBTL1HCAR3LDHA | |
| SCHEMBL19808874 | 0.75 | MAPT (0.47) | MAPTHRH3P2RX3L3MBTL1HCAR3 | |
| SCHEMBL4255729 | 0.74 | RXRA (0.54) | MAPTHRH3RXRAP2RX3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1710233-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239860-A1 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE | ADORA2A, ADORA2B, HTR1F | MAPT 4025/4885HRH3 61/4885RXRA 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.